136 related articles for article (PubMed ID: 34353213)
21. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Henaine AM; Paubel N; Ducray F; Diebold G; Frappaz D; Guyotat J; Cartalat-Carel S; Aulagner G; Hartmann D; Honnorat J; Armoiry X
J Clin Pharm Ther; 2016 Feb; 41(1):47-53. PubMed ID: 26748577
[TBL] [Abstract][Full Text] [Related]
22. Treatment costs for glioblastoma multiforme in Nova Scotia.
Mendez I; Jacobs P; MacDougall A; Schultz M
Can J Neurol Sci; 2001 Feb; 28(1):61-5. PubMed ID: 11252298
[TBL] [Abstract][Full Text] [Related]
23. The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Salem A; Hashem SA; Al-Rashdan A; Ezam N; Nour A; Alsharbaji A; Sughayer M; Mohamad I; Elyan M; Addas A; Al-Hussaini M; Almousa A
Hematol Oncol Stem Cell Ther; 2011; 4(3):116-20. PubMed ID: 21982884
[TBL] [Abstract][Full Text] [Related]
24. Recurrent glioblastoma: Current patterns of care in an Australian population.
Parakh S; Thursfield V; Cher L; Dally M; Drummond K; Murphy M; Rosenthal MA; Gan HK
J Clin Neurosci; 2016 Feb; 24():78-82. PubMed ID: 26549675
[TBL] [Abstract][Full Text] [Related]
25. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
26. 5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(9):1-92. PubMed ID: 32194883
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Uyl-de Groot CA; Stupp R; van der Bent M
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
[TBL] [Abstract][Full Text] [Related]
28. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
Mirza FA; Shamim MS
J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
30. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Weller M; Cloughesy T; Perry JR; Wick W
Neuro Oncol; 2013 Jan; 15(1):4-27. PubMed ID: 23136223
[TBL] [Abstract][Full Text] [Related]
31. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma.
Cloughesy T
Semin Oncol; 2011 Dec; 38 Suppl 4():S11-20. PubMed ID: 22078643
[TBL] [Abstract][Full Text] [Related]
32. Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma.
Weinberg BD; Boreta L; Braunstein S; Cha S
J Neurooncol; 2018 Jul; 138(3):549-556. PubMed ID: 29546530
[TBL] [Abstract][Full Text] [Related]
33. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Messali A; Villacorta R; Hay JW
Pharmacoeconomics; 2014 Dec; 32(12):1201-12. PubMed ID: 25085219
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
[TBL] [Abstract][Full Text] [Related]
35. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
36. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
37. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
38. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma.
De Bonis P; Fiorentino A; Anile C; Balducci M; Pompucci A; Chiesa S; Sica G; Lama G; Maira G; Mangiola A
Clin Neurol Neurosurg; 2013 Jul; 115(7):883-6. PubMed ID: 22959214
[TBL] [Abstract][Full Text] [Related]
39. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
[TBL] [Abstract][Full Text] [Related]
40. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
